Latest / Powering the Future Within / Episode 17: “You Can Create a Market in That Situation”: Inside the Success of Jupiter Endovascular
Transcript
- speaker-0: Welcome to Powering the Future Within, the podcast where we explore the breakthroughs shaping the future of MedTech. I'm Omari Bognight, CEO of ResidentLink Medical. Each episode we speak with a leader who is driving the next wave of medical innovation, advancing technologies that are smarter, less invasive, and more connected than ever before. This is where the future of health takes shape. Let's dive in. Today's guest is Carl Saint Bernard, a seasoned MedTech executive and the CEO of Jupiter Endovascular. Carl has built his career at the intersection of large-scale medical technology and venture-backed innovation. He held leadership roles at companies like Johnson <unk> Johnson in GE Healthcare, where he developed deep expertise in bringing complex technologies to global markets. He then made the transition into earlier stage companies. Leading and scaling organizations while gaining firsthand experience at what it takes to build, pivot, and grow venture backed MedTech businesses. Now, as CEO of Jupiter Endovascular, Carl is focused on advancing next generation endovascular technologies aimed at improving outcomes in complex vascular disease. Carl, welcome to Power in the Future Within. speaker-1: Hey, thank you, Omari. Appreciate it. Looking forward to ⁓ a great discussion. speaker-0: Really, really great to have you on. Appreciate it as well. So you've had a front row seat for several critical advances across the med tech space. What originally pulled you into med tech and what's made you stay? speaker-1: Yeah, it's a great question. You know, ⁓ I think med tech is a a great sort of infrastructure business that everybody touches at one point in their life, either directly through their own health care or health care of a loved one, and you just don't really know much about it from the outside looking in. ⁓ I had an opportunity early to ⁓ meet some people who had worked in in med tech. And I was selling pharmaceuticals at the time. And I just thought ⁓ being actually in the hospital in the ORs with doctors was just way more interesting than than ⁓ detailing ⁓ a doctor in the office. ⁓ so I I just felt ⁓ it it just k kinda called to me that ⁓ that that was something I wanted to do. So at the time I was in the commercial world as a salesperson and ⁓ and then came on as a a sales rep, which I think in our industry is a is a great entree into the med tech world because you really get to see all of these products, competitive products, existing products in your portfolio, new products. You get to see how the doctors react to the technology and how they really leverage it for patient care. You know, you're right on the ground floor from a sales standpoint. It's a hard job. You know, ⁓ a lot of the technologies we had to ⁓ be in the OR at six o'clock in the morning and getting everything ready for the seven thirty start of a surgical day. and then you you're there late ⁓ in the day, but you really learn a ton and it's ⁓ just a blast. speaker-0: Yeah, you're right there on the on the front lines. And and as you say, you know, part of the med tech tradition or industry is really providing that value add either in the OR or in the CAF lab or the E P lab, what whatever it might be. And I think for a lot of us that's a very attractive aspect really to be part of that value add, part of that delivery of healthcare, if you will, behind the scenes. speaker-1: Yeah. Yeah, absolutely. It's ⁓ it's it's really I I look back at that as something I continually think about ⁓ when I evaluate new technologies or new ideas for technologies. I always kind of go back to myself sitting in a in a company Taurus, driving around in my territory and thinking about what I would do with something like that. Like how would I position this technology against the competition and You know, what would the sales rep Carl do in this situation? And and it just sort of grounds me in the reality because all of these all of these technologies need to be explained to the doctors. They need to be trained. ⁓ the staff needs to be trained on how to use them properly. And ⁓ it's gotta be a compelling value proposition to really convince a doctor to do something different, ⁓ than what they're currently comfortable in doing. speaker-0: Yeah. What was the first territory that you were assigned, regionally speaking? speaker-1: Yeah, so ⁓ Los Angeles. Yeah, I was out in ⁓ California and ⁓ you know from a medical device standpoint ⁓ I was working for a company at the time called WEC Surgical, which was then ⁓ bought by LinVitech, became Linvitech, ⁓ was owned by Bristol Myers at the time. And ⁓ we rapidly got deeper and deeper into endoscopic surgery and arthroscopic surgery. So we sold capital video scopes and equipment. We sold disposables, implants, and ⁓ and then a set of reusable tools as well. So it was really broad based. I mean, we had surgical tools, ophthalmolic, ophthalmic tools. We had video capital equipment. ⁓ it was a it was a really cool job just for learning learning the industry. speaker-0: Right. Absolutely. I'm always impressed by those that have territories in the the Los Angeles area, how they're able to navigate the traffic going from speaker-1: Yeah. So yeah, so I I looked at it like I had to navigate traffic, but other people had to you know, bring their equipment into like, you know, two feet of snow sometimes and you know, all kinds of crazy weather. So I you know, I I dealt with traffic and they dealt with blizzards and hailstorms and things like that. So speaker-0: And and as you move from a territory level to a region level area and eventually national and potentially international, I always find it fascinating on the regional differences. You know, one you go from one state to the next or one country to the next and the differences are are pretty pretty dramatic. Did you find that you had to start to adapt your your style of engagement and leadership as you went from a territory to region to to nation nations? speaker-1: Yeah, I I think so. ⁓ you know, I always say, you know, being a national sales manager, you know, really set you up well to run for ⁓ the presidency of the US because you you know, you end up in being in every single city. ⁓ I've been in Sioux Falls like that Johnny Cash song, you know, I've been in every every town, you know. And y you get to just, you learn different different ⁓ styles from people around the country. in the southeast and the northeast and the Midwest across the West and you know, you you really do get a a great sense of of the country in the US, particularly I think when you start thinking about it ⁓ globally, the healthcare system in terms of delivery is very different. ⁓ you know, fundamentally if you're in ⁓ an account in New York, ⁓ and then you're talking to somebody in Portland or talking to somebody again in like Dallas or in the Southeast, the same delivery mechanisms of healthcare exist. You know, there's the you know, there's still CMS and, you know, and health insurance companies and so on that you manage through and that kind of thing. But ⁓ when you go internationally, the delivery of healthcare is very different. ⁓ there's a much heavier government presence in a lot of the decision making relative to medical technologies, you know, so you really have to learn the healthcare systems and the countries that you're dealing in. And and that's something that I think for anyone moving domestically here in the US into international markets, you really need to become ⁓ an expert in those ⁓ in those markets to really understand how to formulate a strategy to be successful there. ⁓ but you know, i having said that, when you start talking to the physicians ⁓ and understanding the patients, that's when things become, you know, come back to the common denominator. You know. ⁓ of taking care of patients, ⁓ doing evidence backed ⁓ procedures and ⁓ and and I think the healthcare from that level is very similar. Right. speaker-0: Yeah, that common denominator which is the the patient and and really kind of addressing their needs. speaker-1: Yeah, exactly right, exactly right. So, you know, while the infrastructure around the doctors is different, you know, the the the things that the doctors care about are very similar. speaker-0: Right. So you've been part of organizations that are very well known for driving commercial leadership throughout the organizations. Looking back, are there parts of your early career that still show up in how you lead today? speaker-1: Yeah, yeah. You know, I think ⁓ I always think back to my earlier days ⁓ at GE Healthcare. ⁓ I had been mostly kind of a field-based, marketing-based ⁓ you know, individual from a career standpoint. And I had this opportunity to become the US sales operations manager for GE Healthcare's diagnostic business. And, you know, it's a big business, obviously. I think at the time it was, you know, three billion dollars in size. ⁓ in the Americas. And I got the opportunity to kind of be the chief of staff for the the VP of sales. ⁓ and, you know, doing things like forecasting for the entire country ⁓ across all of our portfolio products, ⁓ rolling that up with the finance team, making sure we had supply with the operations team and coordinating the SNOP with them. ⁓ developing ⁓ compensation plans. I think at one point I was developing 22 different compensation plans ⁓ for one one calendar year for the different kinds of sales reps that we had and different specialists and things. So we were managing, you know, 22 different sales compensation schemes, you know, looking at costs, you know, base costs and expenses and so on. So At some level, I I would say that role sort of prepared me for the future ⁓ roles I held because I had a chance to really see across the entire organization and really be in the boiler room in terms of how like a big company like GE Healthcare ⁓ ran its commercial operations. You know, so ⁓ from that standpoint I I think, you know, now stepping into any other kind of sales or commercial scenario, I I still kind of think back to those days and really r you know, understand how that made such a big impact on my ⁓ my future thinking in terms of commercial ⁓ strategies. speaker-0: For sure. So so you're at these large organizations, you're having great success, great brands, great products, great technologies, great people. What made you interested into stepping into venture backed environments? speaker-1: Yeah, it's a g it's a great question. I mean, I I had worked at ⁓ G Healthcare and Johnson <unk> Johnson and Abbott. ⁓ great companies, great experiences. ⁓ all three companies are obviously world-class organizations and and it was having great careers at at all those those companies. And I just, you know, felt like ⁓ I had this opportunity to, you know, really be able to go into some smaller companies, startup companies. and really have more of an impact on the culture of the company. And ⁓ and, you know, the concept of taking a single product or technology and developing a strategy, a multi year strategy to bring that to market was really just attractive to me. You know, I I think in the bigger companies, you sometimes you have so many things happening that it's hard to really focus ⁓ on just one thing because there's so many things happening ⁓ I had worked ⁓ at a company called Life Cell, which was a private equity ⁓ funded organization and had a great experience. I mean, it was a a smaller company than obviously the other companies. And, you know, as a board, we made our own decisions on strategy for, you know, all the various functions ⁓ and we we did that as a leadership team. And I really enjoyed that experience and that and that focus, you know. And so when I had the opportunity to join a startup, ⁓ you know, I really was just looking forward to kind of getting into that space and ⁓ again, from an early development standpoint, ⁓ being able to be impactful to those technologies and then bring ⁓ to the market. speaker-0: Was the aspect of risk something that you had to consider and get your mind around? And what did you find potentially surprising stepping into the the venture back world? speaker-1: Yeah, you know, r risk is a funny word. You know, I I guess ⁓ I I ⁓ I did w I forget w which one of the personality ⁓ you know, inventories that that go around and you know, it found that I am like a a high risk taker. And, you know, I I never really considered myself that and I don't think my wife would necessarily say that either, but I guess from a business standpoint, you know, I always felt like that was where the fun was. You know, and and so the idea of taking risk ⁓ in business and doing something that could potentially fail, you know, just seemed like more natural for me to go do. You know, it just seemed like that's where the fun was. And I I would say, you know, ⁓ people ask me about risk in organizations and you know, I I would say there's always risk, right? So in big organizations, you might be in a certain division and a certain function. that you know you may feel secure one year and then ⁓ two years later that division might be sold, it might be downsized, it might be deprioritized. So, you know, then you could be at risk in that situation career wise. and, you know, in a startup it's kind of more existential risk where, you know, everybody's together, we're driving something ⁓ driving a ⁓ a technology and There's a risk in that, but I don't know that it's any necessarily bigger risk than in some of the some of the larger companies and being in different divisions, you know. It's just a different kind of risk. speaker-0: Yeah, yeah, a different type. And it it strikes me, I often talk to people who are moving into the industry and I always talk to them about taking roles sort of like earning currency and over time you build more and more currency. And the b the more currency you have and the more flexible currency that is, the more ability you're able to adapt. Because whether you're at a startup or a large organization, as you say, environments and things change and there's different types of risks. So if you're focused more on building currency in yourself, you're You're more able to adapt to th those types of situations. speaker-1: A absolutely. I think ⁓ you know, that is a maybe an underappreciated asset in business. You know, when you do inventories of people's skill sets for leadership roles, you know, the adaptability quotient for people is a big deal. I I you know, I I think, you know, I I think about strategy and, you know, getting from one point to another point strategically. ⁓ You build a plan and you resource it and begin to execute it, but I can guarantee you you won't get there the way you planned. Right. You know, you're you're something's gonna happen that you're gonna have to change your strategy, your tactics, and readdress the way you're you know, the way you're going forward. And the people that are adaptable and see the changes happening can delineate these are structural changes that I need to adapt to. Those are the folks that survive. and and become successful. ⁓ those that don't see those changes or they're just reluctant to really change, ⁓ I think are the ones who who unfortunately, you know, don't get to the you know, get to the goals. speaker-0: Yeah. And and smaller companies are oftentimes known for being better or good at pivoting. Were there things that you took note large companies do exceptionally well compared to those that are smaller? speaker-1: Yeah, I I think large companies do a wonderful job of creating common culture, a loss ⁓ across large geographies, large numbers of employees, ⁓ different cultures, you know, around the world. They really do a nice job of that. GE's culture, super strong, ⁓ Abbott's culture, super strong and and pervasive, and Jane J's ⁓ culture obviously the same, you know, just super strong, ⁓ uplifting and motivating for for the employees. So I think they do a great job of ⁓ building culture that could be replicated. I think they do a great job of just ⁓ disseminating best practices. You know, like if if a region of the world or a given business is ⁓ doing something that's really outstanding that can be applied to other re other divisions or regions, they do a great job of getting that out and and ⁓ kind of building that into the into the ⁓ standard operating procedures. You know, really just phenomenal. ⁓ I think the harder thing for them to do is to to change strategy, I think. You know, and I I think as a small company, you know, our superpower is the ability to move fast. And I impressed upon that on my team. I I really hate when we have to address the same issue more than a few times. You know, like if we make a decision We need to go. And if we are still kind of a week or two, three, a month later still debating the same question, I think we're losing leverage. You know, it's it's a loss of leverage for the organization because that is what you know, what we're basically here for is to innovate and move quickly. And, you know, sl there's really no excuse for moving slow on a small company. You know. speaker-0: Exactly. Yeah. No, I was interviewing a leader recently and she was impressing upon me how often she would use the metaphor of, Hey, on this decision we burn the boats, guys. Like we're focused on moving forward and moving quickly. There's no no turning back. speaker-1: Yeah, I I think ⁓ you know, in my meetings with the team, I'm always I always say ⁓ one of the things I, you know, consistently say is we're out time. It's like it's like it's like jeopardy, like the bell's off. Okay, what are we doing? What's the decision? We're out of time now. We've got to make a decision and and live with it and go with it. So that's ⁓ you know, that's something that's ⁓ that's important. I think ⁓ bigger companies, you know, don't really do that. I mean, there's too many Things to manage, I think from a risk, you know, risk standpoint. there's a lot of ⁓ interwoven functions that need to kind of weigh in because what could seem very logical on one hand in a big company in one division might have negative downstream consequences to other divisions. So ⁓ there's a lot more of ⁓ you know a lot more time taken in these decisions usually because of the implications. speaker-0: One of the best feelings at these companies is when you really hit your stride and you get momentum and maybe you've been operating through trial or ever error, but you've discovered something that really works, that could work across regions, across country, et cetera. How do you kind of get a feel for this is true momentum that I want to get behind? Time to burn the boats, maybe it's not time based, just kind of a a feel or a sense or you've got data. When do you know you really have momentum and you really want to go? versus you're just having activity and still on the exploration phase. speaker-1: Yeah, it's a it's a great question. I mean, it there's ⁓ there's data and there's analytics that you can do to sort of understand whether what you're seeing is a true signal or or it's kind of you know, caught up in the noise. ⁓ I think there's a a gut element to it that it you know, people think gut is just subjective, but it's really years and years of being involved and seeing how these things evolve and you know, your brain and your gut, if you will. sometimes is a lot smarter. Their first instinct is a lot smarter than some of the ⁓ analytics that can kind, you know, come down. So I I I listen to my gut, listen to customers, you know, and I can not even so much what the customers say in content. It's more of what they say, how they say it emotionally. Like if you've got a new technology in a physician's hands, you know ⁓ recently we we had ⁓ a meeting with some physicians and we were showing them some new technology that we developed. And you know, what was interesting was ⁓ it was almost what they didn't say. Like they couldn't take their hands off of it. They kept playing with it, they were smiling and like sort of winking at each other about this technology. And it sort of that speaker-0: Mm-hmm. speaker-1: sort of nonverbal cue and the way that they interacted with the technology ⁓ led me to believe that we were on the right path, you know, in terms of ⁓ in terms of focus. So obviously there's all the market analytics work that you can do to make sure that, you know, that there's a a pot of goal at the end of the rainbow, you know, with that technology. But I think whether you have a winner or not, is is really more of like the customers, you know, and how they emotionally interact with their the technology. speaker-0: Yeah. I heard it said once that all gut is is your experience being felt. Yeah. So that's right. Yeah. Yeah. If you could somehow transform that into data, so forth, et cetera, but your gut is telling you something because of things you've experienced, things you've seen. I think it was in ⁓ Malcolm Gladwell's book Blink where he would talk about judges knowing that a p a tennis player is getting ready to footfall. And obviously I footfall in tennis is pretty rare, but they would predict it every time. They couldn't tell you what they were picking up, what they were seeing. Just that experience was translating into knowing something was going to happen. speaker-1: I think that's right. I think that's right. I mean, you know, th there's you know, it's hard to pick winners. There's, you know, tens of thousands of medical technologies that are developed and, you know, and trying to figure out which one's gonna be a winner. ⁓ I think you have to have the basics, you know, like a a competitive product. I also think about ⁓ you know, things that are really truly differentiated, meaning if the the rest of the market is competing in one vector, let's just say it's ease of use. ⁓ efficiency kind of a thing. ⁓ if you've got a technology that brings another wrinkle to that, not necessarily ease of use, but maybe there's ⁓ a clinical benefit that ⁓ no one else is really picking up on and your product has a distinctive clinical benefit to it, I think that ⁓ is something that can't be ignored. And, you know, even if it's not something that people are judging that technology on today. ⁓ you can you can create a market ⁓ in that situation and you have it to yourself once you do that. So ⁓ I do look for those situations as well where ⁓ we have an opportunity not just to be part of a market, but to actually craft the market and direct it. speaker-0: Right. And it's an interesting perspective because when you go from the large company, there's a lot that's in the bag. It's multiple products. A lot of times their contracting is more sophisticated. And so if you're going to go to a smaller organization that's a a single product company, essentially, you wanna have something that can't be ignored to use your your terminology. Otherwise, if it's just a little bit better incremental or, you know. matter of preference, you can run into a lot of trouble when you get to the commercial environment. Absolutely. Yeah. speaker-1: No, absolutely. ⁓ I totally agree with that. I think you have to be thinking about ⁓ small company, is your technology truly breakthrough? Is it something that's going to change the market, change how the procedure that you're ⁓ getting into is being done today? ⁓ you're changing the expectations, ⁓ maybe the clinical endpoints of the procedure. You know, so that's the kind of thing that you you really I key in on. when I think about those kinds of ⁓ those opportunities. And you're right, big companies, you know, you've got, you know, you may have a a number of winning, you know, number one market share products, but inevitably you have some other products that are a little bit more, you know, Me Too or commoditized and you're bundling them and you're doing things to sort of sell those, but they're they're just not as sexy, you know, and when you're when you're a startup, you've got to be all about sexy. No, you've got to be all about that. You know, that's the you you've gotta have something differentiated, distinctive, and a really a different perspective ⁓ as you enter a market. speaker-0: Yeah. Well you certainly are affiliated with a company that that seems to have the it factor in Jupiter. ⁓ I'm curious, what was the initial spark behind Jupiter Endovascular? speaker-1: Yeah, you know, ⁓ when I first saw the technology, ⁓ because I w it's it's an interesting technology. The the idea of taking something that's pretty common in interventional medicine, which is a catheter, right? and but then reinventing it, reimagining what a catheter is, ⁓ is something that, you know, you don't think about really. ⁓ but when I saw this this catheter, the fact that it could be as flexible as a a wet noodle, if you will. And then ⁓ you could follow it, ⁓ have it go th you know across, you know, a standard guide wire anywhere in the body. And then once you get it to where you want, you basically then can just transform it into a firm fixed state that it ⁓ stays in that ⁓ an anatomic adaptive position ⁓ and just stays there. It doesn't slide, doesn't move. ⁓ You know, it's like you're creating a new guiding catheter that's tailored for that situation with that patient at that moment, ⁓ every time. And if you want to change it, you make it a noodle again and you can move it any which way you want and then and then fix it again. So that that ability to do that, ⁓ you know, really got my brain racing. ⁓ because a lot of procedures in the interventional space, ⁓ Most of the complications from these procedures don't really have much to do with the actual implant a lot of times, ⁓ or the actual therapy. It's how it's delivered. You know, how the delivery mechanism of that therapy to the the area of treatment, how that's delivered sometimes becomes the the biggest source of ⁓ adverse events, complications, frustration with the doctors. in doing the procedure. So, you know, in this situation, you could pretty much customize your delivery of any ⁓ therapeutic ⁓ implant or or ⁓ device through these catheters and you can basically customize your own delivery system ⁓ for each each one of them. So it just sort of changed the my my perspective and I and I thought about all these interventional ⁓ opportunities that we would have with the technology. So ⁓ and that was the mandate. It was to basically think through a lot of different markets within the interventional medicine space and really determine where the technology could be the most useful. speaker-0: Yeah. That's a a huge advance because historically we've often thought about moving through vessels and having to have a trade off. Either you have something that's pretty stiff that can can help you h hold your position, or you have something that is maybe more flexible and helps you get around the anatomy. And when you think about going through vessels, small vessels inside of the body that you're looking at through imaging. So it's not through direct visualization, it's through imaging. That challenge and that trade off, and as you say, a lot of the safety events that occur might happen because you dissect a vessel or you cause micro trauma to the vessel. And you're always trying to think through as a clinician, what's that trade off between firm technologies and those that can track and navigate and and to have something that potentially can balance both worlds is really, really powerful. speaker-1: Yeah, I I I think it's it's a great you know, when you when you first start in interventional medicine and you go into a calf lab or any interventional suite and you they all have these ⁓ huge racks of ⁓ tools and devices hanging barrel, you know, rack of devices hanging on the wall and and it's massive. You know, you look at this and you're like, How do you know what you're what you're using? You watch a procedure And throughout the procedure, the doctors are putting up different wires and different catheters and different guides, and it's you know, it's like a a plethora of stuff that's open and all these things are all over the table and you you're you're just thinking like how do they know what to use when? And you know, quite frankly, a lot of it is trial and error in each situation. Some situations they can they can, you know, get where they need to go with a certain flexible catheter, but that flexible catheter usually isn't the one that allows them to deliver right, you know, the the therapy the way they'd like. So they have to trade it out for a a a you know, a more stable, ⁓ rigid type of ⁓ you know catheter. But then you have to sort of do this trade off and so you're taking things in and out constantly and try to trial and error which one works the best before you go. You know, in our situation, particularly with like pulmonary embolism, for example You know, this is kind of an urgent procedure ⁓ that's happening and you don't really have the time to do a lot of the normal i you know trial and error. You want to get in, you wanna get to the clot and get it extracted as soon as you can. So, you know, having something that is as flexible as our catheter that can basically be ⁓ placed in direct opposition to any clot ⁓ in the pulmonary artery and then aspirated quickly, ⁓ really makes a big difference in terms of ease of use and speed procedure. So y you know, really when you think about pulmonary embolism thrombectomy, it's it's all about the catheter. You know, it's a catheter based procedure. The usually the ⁓ therapeutic agent is suction. So it's not very complicated. So the catheter plays a huge role in ⁓ in the procedure. speaker-0: Right. speaker-1: And we felt as if because our catheter is so unique and ⁓ is so flexible and manageable within the pulmonary ⁓ arteries, that it gave us an opportunity to really do something different with this procedure and kind of transform it into something that ⁓ is a lot easier to do, a lot quicker to do, and hopefully more therapeutic ⁓ than some of the current ⁓ commercial options. speaker-0: Yeah, I can imagine that this application would be incredibly powerful in in this space, given the fact that navigating to the pulmonary arteries historically has been challenging. It's very i it's very urgent. You have to remain stable as you're suctioning out the clot, you're approximate to the lungs. There's a lot that's happening. ⁓ be able to balance flexibility with structure and being rigid, I think would be incredibly powerful. Yeah. speaker-1: Yeah. So that was our first, you know, it's a platform technology and we've always viewed it as such. But our first application is ⁓ pulmonary embolism. ⁓ we just thought, you know, it's the third leading cause of CV mortality, cardiovascular mortality. it's something that is undertreated and under-recognized. I've heard physicians say that ⁓ you know, it's number three in in cardiovascular mortality, but It might actually be number two. ⁓ just because it's it's underdiagnosed so ⁓ significantly. It could be maybe the second and ahead of stroke even. and you know, the implications can be devastating, you know, obviously. And what we found also is about a third of patients have what they call ⁓ post PE syndrome. So they have a pulmonary embolism, they survive the index event, they're treated. ⁓ and then they go home and but they never really recover fully. You know, they never really get back to where they were before the the pulmonary embolism. And that that's anywhere the in the literature from a third to half of the patients have have some residual effect of that pulmonary embolism. ⁓ not being able to walk the same ⁓ distance ⁓ they they were before, climb stairs. ⁓ so on. So their lives are are definitely impacted. And, you know, we think a lot of that has to do with incomplete treatment during the index procedure. So, you know, we think with our flexibility and ⁓ access that we can get within a a pretty complex pulmonary artery structure, you know, we think that our technology will actually do a more complete job of ⁓ removing all of the clot and hopefully getting more patients back to the normal hemodynamic state that they had before they came in. speaker-0: It's very interesting, not just thinking of it in terms of pulmonary embolism being a morbid pr potentially a morbid condition, which obviously it is, but also just thinking through what's the burden of the disease and so just the ability to treat it in a more complete fashion, allowing for for additional benefit to patients. Yeah. speaker-1: Exactly. I I think, you know, ⁓ in our you know, the early ⁓ players in the space did a great job in in ⁓ developing a technology to save people's lives. And I think all of us are are focused on that initially. But, you know, once you once you you've stabilized a patient, you've removed most of the clot, I think when you're in there, if there's more clot that can be removed, ⁓ you know, you should be able to to access it and successfully remove it. ⁓ and that's one of the things that we think our system is gonna be really ⁓ you know really attuned to to do. speaker-0: So as you mentioned, it's a platform technology. And one of the curses I see with a lot of entrepreneurs is having a platform that can treat so many different areas. And you landed on a great one, the pulmonary embolism. How did that decision making process go through, knowing you have a platform? Is there discussions of of maybe taking in other directions, maybe trying to tackle other indications at the same time? It seems like you've done a really nice job narrowing in the first application and being incredibly focused, but I'm curious as to How that transpired. speaker-1: Yeah, it's it it's a great question. I mean, it's still a challenge as we think about other applications. And you know, there are a number of things that we could be involved in, looking at structural heart, ⁓ mitral valve, ⁓ tricuspid valve. So a lot of those things I think it came down to ⁓ you know, technically at some level on one hand, what is it that we can do with the core competencies we have within the organization? And ⁓ developing a pulmonary embolism thrombectomy system fit neatly within the core competencies of the team. So ⁓ it made sense for us to go down that from a pure technical standpoint. ⁓ we thought also that the core of our technology is at the core of the solution that we're providing. You know, this catheter is the core ⁓ item, if you will, in a pulmonary ⁓ thrombectomy procedure. And, you know, we had a unique ⁓ a unique ⁓ opportunity to to to deliver that. So, you know, that was one of the real key things was, you know, can we do that? Then the market size, you know, all the usual things. How big is the market? How under penetrated is it? ⁓ we attribute a lot of the underpenetration to ⁓ kind of ease of use. You know, there's not a lot of other procedures where interventional radiologist or cardiologist are routinely delivering twenty plus French devices through the heart. ⁓ so, you know, ⁓ the the challenging ease of use part of it we thought we could also address. And ⁓ and then the efficacy part of it. ⁓ you know, we thought we'd be able to access ⁓ more routinely, consistently different vessels that aren't typically accessed, and then ultimately do a much more complete job of ⁓ of thrombectomy. speaker-0: Right. Fantastic. And so you've you've raised a significant series B and completed enrollment in a pivotal trial all in the last several months. That definitely feels like great momentum. What have been some of the critical small steps that have led you to these larger milestones? speaker-1: Yeah, I you know, you raising money is rough. You know, ⁓ it's rough. It's a rough thing to do. you know, you need to have good board members, I would say, you know, aligned board members. When I you know, ⁓ it it it's it's such an important ⁓ part of raising money because a new investor is gonna look at your current network of investors, your current ⁓ syndicate, and really understand how they fit in. to that syndicate. So they're not just evaluating your technology. They're not just evaluating maybe you as a CEO, as a leader, but they're also thinking about their return, obviously, and and how their ⁓ how their ⁓ goals are going to fit within the context of the existing organization that you've built. So, you know, that part of it is ⁓ something that's important to understand and ⁓ And work with your board members to be supportive of the fundraising process, and and having a realistic impression of what that means. You know, at some level, you know, you hear kind of contradictory things where like the board will say, You need to raise more money. And then you raise money and they're like, Well, not under those terms. You know, that's gonna dilute us and you know, and like, well, raising more money is gonna have that effect. And speaker-0: Okay. speaker-1: You know, so it it's it's part of the the management of of of that fundraising process. look, I I think every time you raise money, the environment's different. So what you learned in series B will not necessarily be what you have to focus on in series C. ⁓ you know, the operating plan changes. speaker-0: Yeah. speaker-1: And the environment changes, the competitive environment, the macro environment changes. So, you know, you really need to think about every round as like ⁓ kind of a rebirth of your company. You know, you're basically having to rethink your whole organization and raise money based upon that new vision that you have. ⁓ you obviously have milestones that you hopefully would have achieved leading into that that give people ⁓ you know, a sense that you can execute, you know, so that's that's important. But ⁓ I would be ⁓ I always think about each round as like a brand new company. You know, whole new ⁓ horizon, a whole new operating plan, and a set of milestones that you want to achieve with those ⁓ with those funds. ⁓ and I think being really clear about that, that's another thing. I I've seen pitches over the years where It's not really clear what they're going to do with the money other than sort of more development or something. And being really crystal clear on the milestones that you're going to achieve with that additional funding and how that's going to increase the value of the enterprise. I I think, you know, that's something you can't really stress enough with investors. So yeah, there's a lot of little tactical things that to manage through, but ⁓ but I think, you know, th those are some of the big thoughts around raising raising capital. I would also say start early. You know, like if you think, you know, it's going to take you six months to raise money, you know, s you know, start night a year into it. Start talking people. a lot of the the people who invested in my last round, we've had ⁓ upwards of twenty meetings over that timeline. ⁓ so, you know, these are Zoom calls, live meetings, that we had due diligence meetings all the way along. So, you know, it it's not a couple of calls, a couple of meetings, a PowerPoint pitch, a follow up, and then here's a check. You know, it it ends up being ⁓ they really get to know you as a leader and your team, ⁓ as a leadership team, and you get to know them as well in terms of their priorities. speaker-0: Right. Right. And as you say, an ideal situation, you have an investor group, a syndicate, a board that is sort of aligned on milestones and aligned on what are the value drivers. But oftentimes based on timing or other elements, it can be hard to to maintain or to initially have that alignment. So I would think that interactive process would be helpful and not them just interviewing you, but also you getting a sense of am I going to have an aligned board? Am I going to have an aligned investment? ⁓ syndicate if if I bring in this group. speaker-1: A absolutely. I think that's that's one of the most important elements, I think. Because I think ⁓ you know, the real savvy investors really look at your current syndicate of i of ⁓ investors and they think to themselves, Hey, if this guy has to raise another two rounds Right, you know, is there enough dry powder around the table to sort of fund those next two rounds? And, you know, if they think not, ⁓ or there's going to be a struggle with the next round, so to speak, then it becomes, you know, maybe the initial investment doesn't make sense in that case, you know. So you know, getting your board aligned on the fundraising strategy and ⁓ how we're going to go forward is a big deal. That's ⁓ sometimes I think that's forgotten where people just start talking to new investors and they just start rolling and and they don't take into account some of those speaker-0: Yeah. speaker-1: some of those ⁓ alignment activities. speaker-0: We're starting to see some very large raises earlier on in series A, Series B. We've seen a couple that have crossed a hundred million dollars in a series A or series B. A lot of that feels as though it's really investors trying to protect their interest over over the long term. Is that a trend that you're starting to see? Is that something that you think will continue to happen? speaker-1: Yeah, I I think so. I mean, you know, I think there's gonna be ⁓ a move to or like a move to quality where they see this technologies have the opportunity to really transform healthcare or transform a certain segment, you know, in the in our space. And moving in earlier with more money ⁓ to put to work there, I think it ⁓ allows the company to generate more value. ⁓ and really not focus as much on ⁓ fundraising, but just execution. You know, I I think if you get companies that are in, you know, kind of an annual fundraising mode, you know, you have to wonder like who's running the company and executing in the background, you know, as as the leadership is kind of consumed by the fundraising process. So, ⁓ and if you're in that kind of annualized fundraising, it it becomes a it becomes a burden, you know, ⁓ just from an operational standpoint. So I do think you're gonna see these really unique ⁓ technologies really raise a lot of money and put themselves in a place where they don't you know maybe they don't need another raise for two years or three years, but they can get really far down the road, they can finish clinical trials, potentially get an FDA approval. You know, those kind of things. ⁓ you know, I think that's a that's a big move. You're you're also seeing a lot of interest in these build to buy ⁓ opportunities where, you know, they're working with a VC, a startup, ⁓ a VC and maybe, you know, a strategic OEM. And, you know, it's ⁓ they're they're building the product. There's an option to buy it at the end of that, but you know, the the VCs are funding a lot of that. So kind of the same concept where, you know, you're funding the execution and you're putting enough money into play so that the management team doesn't need to go out and raise money and bring in new investors continually and manage that. They can focus, you know, primarily on execution. speaker-0: Execution. And focus is such an important word and being able to execute is so important. So so you finish raising this round and I can imagine, you know, the day that it's closed, you probably have team members saying, Okay, this is great. ⁓ I know we're focused on on PE. However, there's all these other opportunities we could also start to explore. How how do you keep that team focused? Do you kind of segment then off a different group to explore other areas while you have one group remaining focused on your original indication. What what's sort of the method behind keeping the team focused? speaker-1: Yeah, you know, I I think ⁓ it's a great question because you know, we struggle with that right now, honestly. We have more ideas than we have people to execute on them. So, you know, I end up saying no a lot more than I like to say no. But ⁓ you know, I think the team having the team really understand their priorities, and you know, n not just the leadership team, but the entire organization. We're still small enough where You know, I can talk to every person in my organization. I know them. ⁓ I know what they're working on. And ⁓ we can stay focused on bringing like our current product that we finished our clinical trial, we're ⁓ currently rolling up all the clinical results. ⁓ we're writing our clinical study report to submit to the FDA. So all of these things are happening and different people are involved. You know, and that's a priority. So, you know, that's that's the focus of the organization. If somebody needs support to do any of those things, we make that support available. ⁓ but we still have enough people working on some of the ⁓ some of the other breakthrough technologies. So, you know, right now we have this unique catheter design, but it's really pretty large. You know, we have a twenty six French and an eighteen French version. The majority of interventional medicine, as you know, is probably twelve French and smaller, you know, fourteen French maybe and smaller. So ⁓ we're working on smaller form factors for that technology, for the current technology at the core, where we can do ⁓ standard coronary work, standard ⁓ peripheral vascular work, some neurological work as well. ⁓ so we're we're working to sort of miniaturize the technology that we developed at a 26 French size and to be able to get that down to 12, 10, 8 French sizes in ⁓ and so there's a team working on that actively. and we're right now we're kind of application agnostic, I would say. ⁓ there's a number of different things that we could do, but the the first thing is to show that we can. Deliver this technically and make it a product. And then ⁓ and then we can figure out which market ⁓ we want to address. You know, are there adjacencies to the current PE market that could take advantage of that technology? ⁓ are there new markets that really have huge unmet needs? You know, that's another opportunity for us to look at. So the first part is kind of de risking it from a technical standpoint. The second part is figuring out which clinical market we're gonna go after. speaker-0: Right. That's a really interesting way to think about it, which is you you have your first clinical at application, you're advancing that and supporting that, and now you're advancing the platform itself. ⁓ and as the platform itself continues to advance and you'll explore other indications and approaches and as you say, you'll probably look to leverage off of of pulmonary embolism to start with adjacencies and e expand from there. speaker-1: Yeah. Exactly. And you know, the physicians are great. ⁓ you know, they have a lot of great ideas as well. ⁓ you know, some of them are big ideas, some of them are medium-sized ideas, you know. So you know, we're we're really tapping into our KOL group. And I think that's another th ⁓ thing that we've been ⁓ been really focused on is how do we broaden our ⁓ base of ⁓ KOLs. So, you know, we have great ⁓ group of folks that are in the ⁓ PE arena and they also have expertise in structural heart. A lot of the KOLs we work with have expertise in ⁓ PCI and ⁓ peripheral vascular work. So we're able to kind of utilize that ⁓ to kind of think about other opportunities. Even, you know, talking to cardiothoracic surgeons and kind of exploring ideas around, you know, what are currently procedures that they do as an open procedure that they wish they could do from a endovascular standpoint. And there's a potential to convert some of those. speaker-0: Interesting. And as the the the diameter and the French size gets smaller and smaller, there's a lot of advances happening in neurovascular. You're gonna start getting some some calls from the neurovascular world too, I can imagine. Absolutely. speaker-1: Yeah, anywhere where there's really torturous anatomy that has to be navigated and then you want to deliver something at the end of that navigation, we think we can play a role. speaker-0: Yeah. So what does what does success look like for Jupiter over the next three or five years? speaker-1: Yeah, it's a great question. I mean, you know, it depends upon the applications we hit on and and ⁓ you know how broad the portfolio really becomes. ⁓ obviously, you know, there's a lot of interventional companies that could use technology like this, not just for a PE ⁓ application, but could use it in a whole host of other ⁓ existing markets they're already in. So we think ⁓ you know, we could be potentially a a company that might be of interest to a bigger, you know, global strategic OEM. ⁓ if we can get a number of these platforms up and running commercially, ⁓ we think IPO is an is an opportunity. You know, if we can build out a five to ten year growth story, we think that that's another interesting opportunity for us as well. and, you know, and there's also the the opportunity just to grow the business. And, you know, you know, from a private ⁓ support standpoint, we have great investors now. The more ⁓ that we sort of expand the portfolio, the more attractive, the more valuable the company becomes. So ⁓ we think we'll be able to fund your growth either way, whether it's through the public or private markets. ⁓ so the key thing is for us just to stay focused on the core technology and and keep growing the business and and exploring these new areas because That that's what's gonna really dictate the direction that we have in the future. speaker-0: Right. Yeah. If you build a great organization, build a great business, you have this optionality and then you know the right ⁓ the right opportunity will come come to you. You don't have to go to it. Yeah. Yeah. speaker-1: Absolutely. That's the key. That's the key. So that's what we stay focused on. You know, we we don't try to build a business to sell. You know, we sort of build a business to really endure. And ⁓ you know, we think that's a better formula for success overall. speaker-0: Right. Well it seems as though you've done a tremendous job taking all the learnings at some of the larger organizations and infusing that into kind of the startup universe. What what advice would you give to someone who's been at a larger corporation for a significant period of time and is now considering pivoting toward a venture backed startup? speaker-1: Yeah, yeah, it's a good question. I I think you have to find a good balance of ⁓ things that you've done in the bigger organizations that were more risky within the organization, things that might have been you kind of ⁓ jumped off into a new division or had done some integration of a new acquisition. you know, just taking more risk within the bigger context of the company and really highlight those. ⁓ you know, when you're talking to people about opportunities in the startup world. ⁓ I think ⁓ you also have to, you know, be able to really take some of the consistency and best practices from the big company and make them sort of bite-sized so you can implement some of those as appropriate in the smaller company. ⁓ you don't have to forget everything you've known in a big company. You just need to make it, you know, kind of a a little bite size. you know, ⁓ piece of that where, you know, a startup company can still stay nimble, can still stay innovative and flexible, but but still put in place some of those best practices. ⁓ like for example, for me, I, you know, you know, the the GE ⁓ HR process for me was really an eye opener, really thinking about HR as a force multiplier within your organization. Yeah, at a time where a lot of companies just saw that as more administrative work, you know, in terms of managing your your workforce. And, you know, GE saw it as a source of of ⁓ strength and resiliency in the organization and big big focus on that. And I still ⁓ interview every single person in the organization that we bring in. ⁓ we have regular reviews of how people are doing, focused on development, skill development. looking at roles and organizations, making sure they're optimized for efficiency and and execution. So, you know, that focus on on the people side of things ⁓ is a is a big ⁓ priority for me. And I and I I so I brought that over with me from like a big company. but I still have to realize you know I don't have the scale of GE. So I have to make this a little bit more ⁓ manageable for the size company we are. speaker-0: But but overall it sounds as though you would would encourage people to to explore it if it's something they're interested in. ⁓ speaker-1: Absolutely. I I look, it's a it's a part of the med tech ecosystem ⁓ that is ⁓ that needs to stay vibrant and needs to be successful. And I think the the biggest learning from a big company is at some level in a big company you can be super senior in the organization and never really have to think about where the money is coming from. ⁓ you know, in in a big company. You know, like there's money, so you don't have to Now getting your share of the money for your budget for the next year is is always a challenge and and and that's where the the challenge is. But you know, where the money is coming from isn't necessarily you don't spend much time thinking about it. In a small company, you do. And I I think ⁓ one of the bigger learnings for someone coming over to a startup is really thinking about, you know, fundraising and how to fundraise how to structure your business plan around your fundraising, you know, and really managing that part of it. Cause, you know, figuring out where your money's coming from and how much you have and how do you build a strategy with how much you have and how long will it take you to get there and then when do you have to raise again and so on, like all of those kind of considerations, you know, you don't have to think about and it's You just have to be open to really learning on that when you come in, 'cause there's a there's a lot to learn there. speaker-0: Right. Absolutely. Yeah. When you enter the startup universe and your decisions start to become existential, you develop a new muscle, a new discipline, and it's really actually as powerful in that sense. Yeah. speaker-1: It is. It really is. I I think it's ⁓ you know, the other nice thing about it is if you're successful in the space, you know, then your reputation sort of precedes you within the space. And, you know, I I think from that standpoint you have maybe more stability 'cause now you're a known quantity within within the ecosystem of startup. ⁓ but but that's probably the biggest lift I think for someone from a big company going to a startup is just getting themselves ⁓ up to speed. in ⁓ in that arena. speaker-0: Absolutely. Well this this has just been a tremendous conversation. Really, really enjoyed it and we're very much looking forward to seeing Jupiter's progress a lot on on the forefront there. That's really ⁓ exciting. Absolutely. speaker-1: Yeah, absolutely, Amari. I I thanks for having me on. And yeah, I I'd love to come back and kind of give the team an update on what we've been doing. ⁓ as ⁓ as the company progresses, I'd be happy to to come back on. speaker-0: Fantastic. Let's definitely make that happen. Absolutely. And thank all of you for joining us on Powering the Future Within. If this conversation inspired you, follow the show and share it with your MedTech community. I'm Omari Bachnight. Stay inspired and keep innovating.